stoxline Quote Chart Rank Option Currency Glossary
  
Sonnet BioTherapeutics Holdings, Inc. (SONN)
1.86  -0.11 (-5.58%)    03-28 16:00
Open: 1.97
High: 1.97
Volume: 70,343
  
Pre. Close: 1.97
Low: 1.8
Market Cap: 6(M)
Technical analysis
2024-03-28 3:53:35 PM
Short term     
Mid term     
Targets 6-month :  2.42 1-year :  2.73
Resists First :  2.07 Second :  2.33
Pivot price 2
Supports First :  1.63 Second :  1.36
MAs MA(5) :  2.03 MA(20) :  1.97
MA(100) :  1.59 MA(250) :  4.7
MACD MACD :  0 Signal :  0.1
%K %D K(14,3) :  48 D(3) :  56.3
RSI RSI(14): 48.3
52-week High :  26.39 Low :  1.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SONN ] has closed above bottom band by 31.0%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.03 - 2.05 2.05 - 2.06
Low: 1.87 - 1.89 1.89 - 1.91
Close: 2 - 2.03 2.03 - 2.05
Company Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Headline News

Tue, 19 Mar 2024
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy ... - Kansas City Star

Tue, 19 Mar 2024
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy ... - Chronicle-Tribune

Tue, 12 Mar 2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) Down 10.63% in Premarket Trading - InvestorsObserver

Mon, 11 Mar 2024
Where Will Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Go Next After It Is Up 1.06% in a Week? - InvestorsObserver

Mon, 11 Mar 2024
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in ... - Yahoo Finance

Thu, 29 Feb 2024
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.71e+006 (%)
Held by Institutions 11.7 (%)
Shares Short 167 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.445e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -6 %
Return on Assets (ttm) 866 %
Return on Equity (ttm) -175.9 %
Qtrly Rev. Growth 129180 %
Gross Profit (p.s.) -45.05
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 2.48
Stock Dividends
Dividend 0
Forward Dividend 254070
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android